Back to search

Peptide record

TPDB92534

iRGD Anticancer Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92534
iRGD
Anticancer Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides
Cancer-related peptides Delivery and barrier-penetrating peptides
Peptipedia BBPpredict CPPsite3.0 MLCPP 2.0 StackTHP StackTHPred TumorHoPe2.0
standard
No
A 9-aa standard natural multi-activity (Anticancer, Blood-Brain Barrier, Cell-penetrating Peptides, and other sources) peptide sequence curated from Peptipedia, BBPpredict, CPPsite3.0, and other sources, with an available 3D structural model.
N-terminal: ST-4
Sequence
CRGDKGPDC
Physicochemical Analysis
C35H59N13O14S2
ANEQHILMFSTWYV
DCG
950.05
6.09
2
2
0
-0
4.25
-1.422
0.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
125
13.16
2
Residue Composition
number
0
A
1
R
0
N
2
D
2
C
0
E
0
Q
2
G
0
H
0
I
0
L
1
K
0
M
0
F
1
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 2 C: 2 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 0 K: 1 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C35H59N13O14S2
950.05
6.09
-0
4.25
-1.422
CendR (R/KXXXR/K), RGD
ST-4
Evidence Records 1 records
Evidence 1 Activity

Activity

Tumor-homing Peptides

Target

Tumor vascular endothelium, tumor cell
Targeting
Multiple tumor
Integrin αv, Neuropilin-1

Source & Reference

TumorHoPe2.0
TumorHoPe2
An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy
2020
Song Y et al. Int J Pharm. 2020 Aug 30:586:119498.

Other

Source Activity Label Source Definition
Tumor-homing Peptides
TumorHoPe2.0 experimentally validated tumor-homing peptide annotation.
B16F10, 4T1
B16F10 tumor-bearing C57BL/6 mice and 4T1 tumor-bearing BALB/c mice
Synthetic
Superantigen mutant ST-4
Additional Detail Fields 3 fields
Superantigen mutant ST-4
B16F10, 4T1
B16F10 tumor-bearing C57BL/6 mice and 4T1 tumor-bearing BALB/c mice